Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case Report

Case Report

Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case Report

Margil Ranpariya ^*
Alexus Ludwig
Elizabeth C. Rosen
Robert L. Glover

University at Buffalo, State University of New York: Buffalo, United States.

*Corresponding Author: Margil Ranpariya, University at Buffalo, State University of New York: Buffalo, United States.

Citation: Ranpariya M., Ludwig A, Rosen E., Glover R.L. (2024). Seizure Reduction with Cenobamate in a Pediatric Patient with Refractory Generalized Epilepsy: A Case Report. Clinical Case Reports and Studies, BioRes Scientia Publishers. 7(4):1-2. DOI: 10.59657/2837-2565.brs.24.197

Copyright: © Margil Ranpariya, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: October 28, 2024 | Accepted: November 12, 2024 | Published: November 19, 2024

Abstract

Keywords: seizure reduction; cenobamate; pediatric patient; refractory generalized epilepsy

Introduction

Cenobamate (CNB) is a relatively new anti-seizure medication (ASM) that has received approval from the Food and Drug Administration (FDA) for the adjunctive treatment of focal onset seizures in adults. Emerging preclinical data suggests that CNB may also be effective in the management of generalized epilepsy [1]. Recent clinical evidence supports this potential, with a case study demonstrating that CNB can lead to a significant reduction in seizure frequency, with patients experiencing a reduction greater than 50% [2]. Moreover, a retrospective data analysis has indicated that CNB can significantly improve seizure control in intellectually disabled patients with drug-resistant epilepsy, allowing for a reduction in drug load [3]. In another study, CNB showed promise in older adults with uncontrolled focal seizures, suggesting its benefits may extend across different patient demographics [4]. We present a case of a pediatric patient with refractory generalized epilepsy who, upon initiation of CNB treatment, experienced a clinically meaningful decrease in seizure frequency, aligning with the broader trends observed in recent research.

Case Report

The patient is a 17-year-old Hispanic right-handed male with refractory genetic generalized epilepsy with multiple seizure types including eyelid myoclonia and absence seizures. His seizures began at 9 months old with staring spells and behavioral arrest with eyelid myoclonia, occurring at least 10 times per day. Around age 14, his seizures progressed to episodes of impaired awareness with facial and upper extremity twitching. He was found to have variants of uncertain significance in PECX5, SPTAN1, SZT2 on genetic testing and microcephaly identified on MRI brain.

In 2023, the patient was presented to our institution in status epilepticus with bilateral facial and upper extremity twitching. At the time of admission, the patient was taking six anti-seizure medications: valproic acid, levetiracetam, lacosamide, ethosuximide, clobazam, and zonisamide. During this admission, long-term video EEG (vEEG) monitoring revealed frequent electro-clinical seizures. These seizures manifested as eyelid myoclonia and impaired awareness, accompanied by generalized spike wave and polyspike wave discharges. Various anti-seizure medication (ASM) combinations were attempted during his admission, including his home ASMs, perampanel, phenobarbital, and lamotrigine. Minimal improvement occurred until cenobamate was initiated. After 20 days of admission, the patient was discharged on a regimen of levetiracetam, phenobarbital, topiramate, clobazam, perampanel, and a titration package of cenobamate.

Initially post discharge, he continued to have 6–8 typical seizures per day, each lasting 10–13 minutes. Upon reaching optimal dose of cenobamate 200mg, he began experiencing greater than 50% seizure reduction with average 1–2 seizure a day, including periods of up to 3–4 days with complete seizure freedom. He currently remains on cenobamate 200mg daily in addition to maximum doses of levetiracetam, clobazam, topirmate. He was able to successfully wean off of phenobarbital and perampanel in the outpatient setting. He will be undergoing implantation of a responsive neurostimulation (RNS) device in the bilateral centromedian nuclei in hopes to optimize his seizure control.

Discussion

Currently, CNB is approved for treating focal onset seizures in the USA and Europe. Randomized controlled trials have demonstrated a ≥ 50% reduction in seizure frequency when CNB is used as an adjunctive treatment at a dosage of 200 mg/day [5]. Currently, the efficacy of CNB in primary generalized epilepsy syndromes is unknown and in the process of being studied in clinical trial. The proposed mechanism of action for cenobamate is via blockage of persistent sodium channel currents as well as positive allosteric modulator of the γ-aminobutyric acid-A (GABA-A) receptor [6, 7]. Previous preclinical studies of CNB have demonstrated the potential for it to be a broad-spectrum anti-seizure medication useful for the treatment of both focal and generalized epilepsies [5, 7].

In a recent small case study, 5 out of 6 patients with frequent generalized tonic-clonic (GTC) seizures experienced a ≥ 50% reduction in seizures. The study included a total of 13 patients: 4 with genetic generalized epilepsy (GGE) and 9 with combined generalized focal epilepsy (CGFE). Within the same study, a 16-year-old patient with eyelid myoclonia and absence seizures experienced a 30% reduction in seizures. Additionally, a 20-year-old patient with eyelid myoclonia, absence seizures, and GTC experienced a 100% reduction in GTC [2]. Our case demonstrates the efficacy of utilizing CNB in a patient with refractory generalized epilepsy. Although the patient did not experience complete seizure freedom, he did however have a significant reduction in seizures that has improved his quality of life allowing him to resume his education and partake in extracurricular activities. Our case report adds to existing sparse literature of CNB use in generalized epilepsy. A larger randomized controlled trial is warranted to confirm efficacy of CNB in generalized epilepsy.

References

Sharma R, Nakamura fM, Neupane C et al (2020) Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate. Eur J Pharmacol, 879:173117.
Publisher | Google Scholor
Agashe S, Worrell G, Britton J (2023) Cenobamate in Generalized Epilepsy and Combined Generalized and Focal Epilepsy. Neurol Clin Pract, 13:200133-200110.
Publisher | Google Scholor
Friedo AL, Greshake B, Makridis KL, Straub HB (2023) Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction. Front Neurol, 17:1209487.
Publisher | Google Scholor
O’Dwyer R, Stern S, Wade Safety and Efficacy of Cenobamate for the Treatment of Focal Seizures in Older Patients: Post Hoc Analysis of a Phase III, Multicenter, Open-Label Study. Drugs Aging, 41:251-260.
Publisher | Google Scholor
Chung SS, French JA, Kowalski J (2020) Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 2:2311-2322.
Publisher | Google Scholor
Rissardo JP, Fornari Caprara AL (2023) Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature. Medicina, 59:1389.
Publisher | Google Scholor
Löscher W, Klein P The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs, 35:935-963.
Publisher | Google Scholor

Delia Teresa Sponza

"Journal of BioMed Research and Reports has created a diverse portfolio in peer review process and provides a wide range scientific and medical novel papers to the scientists. This journal publishes high-quality, peer-reviewed content across all levels of professional development and corporate research and development."

Fatema Tashrifwala

I would like to thank the editorial team for their timely responses and consideration in the publication of my paper. They have been very helpful and accommodating, Lastly, being an open access journal, the published work is freely available and accessible to readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nikhil Vitthal Dayama

I would like to thank the editorial team for their timely and prompt responses and consideration in the publication of my case report. Being an open access journal, it will be great help for the readers to learn the new things without any cost. I would encourage the authors to publish their research in BioRes Scientia and I am happy to be part of this journal.

Boubacar Ahy Diatta

I warmly thank the editorial team for the excellent work they do for continuing medical education in Dermatology. I was able to discover with joy their professionalist, their support and above all appreciate their social generosity on the access to the magazines which is free. This allows an update of scientific knowledge to the entire scientific community. I gladly recommend authors for publication in this journal.

Professor Rajko Igic

The editor of JBRR helped me during the whole process, mainly to eliminate some typographical and other errors. It hastened this publication to be published quickly. Although it is a short text, I believe that the content is important for all medical and other scientific disciplines because eventual addition of the iC citations to citation of the paper would lead to proper assessment of the author's contribution.

Dr Tewodros kassahun Tarekegn

I am thrilled to have had the opportunity to publish my research article in this prestigious journal. The entire process of peer review and publication support provided by the editorial office was exceptional, and it fortified my belief in the quality of my research study. The rigorous peer review process ensured that only the highest quality research was published, and the feedback from the reviewers was extremely helpful. I appreciate the journal's commitment to open access publication, enabling my research to reach a wider audience. The easy-to-use online platform streamlined the submission, peer review, and publication process, and I would confidently recommend this journal to any author looking for efficient, rigorous, and high-quality peer-reviewed publication.

Francis Okello Ooko

I was impressed by your author-centred approach whereby you maintained constant and timely communication with us from the time we submitted the manuscript to acceptance, each time providing critical suggestions to improve the manuscript. In addition, we are encouraged by the thoroughness of your editorial team in checking the originality and overall, quality of the work. Which I believe is very encouraging to other researchers and authors who wish to publish their work in your journals. The published work and the information imparted is freely available and accessible to a wide spectrum of readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nidhi Sapolia

I would like to thank the editorial team of their timely response and guidance in the publication of my case report. They have been extremely helpful at all stages. Being an open access journal, it is of great help for the readers to learn new experiences in different fields, I would highly recommend this journal to authors for high quality peer-reviewed publications.

Dwight L Mckee MD CNS ABIHM

I am very impressed by the high quality of the papers published by the International Journal of Clinical and Molecular Oncology. The editors of this journal are a pleasure to work with, as they are highly responsive even to numerous last minute changes in the manuscript that I recently published with them, and the changes are made on-line the same day they are received. I highly recommend this journal to anyone working in the oncology field, and also value it as a source of cutting edge information in the field.

Kyaw Swar Thet

I would like to thank the editorial team for the opportunity to publish our case report in this prestigious journal. I am very impressed by their timely and efficient handling of the submission, peer review, and publication processes. As residents of a developing, low-income country, we greatly appreciate the discount on submission charges. I hope that as an open access journal, it will facilitate easy access for readers to update their scientific knowledge. I highly recommend this journal for high-quality, peer-reviewed publications. I express my sincere gratitude to the editorial team for their excellent work.

Michel Farah

I would like to thank the editorial team for their quick response and support. The publication support and editorial office were excellent and very helpful. I am happy to have my research article published in this prestigious journal. Our previous case report published in this journal was very successful and viewed by many physicians worldwide.

Kristina Dimitrijevic

I am very positively surprised by thе International Journal of Biomedical and Clinical Research, as well as by the review process itself, which is carried out in a high-quality, timely and professional manner. I am glad that my articles are part of this journal.

Hamid Kasim

I had the pleasure of working with your esteemed journal. I testify that the peer review process was effective and quick, the support from the editorial office is very professional, respectful and friendly and the quality of the review is objective and accurate. I am grateful for the opportunity to work with International Journal of Biomedical & Clinical Research and looking forward for more future cooperation.